Patients with ACLF should Receive Priority on the Liver Transplant Waiting List

There is a lack of specific drug for a comprehensive medical treatment for ACLF. Moreover, the novel treatment options are in premature stage. There is no cure for ACLF on the background of high shortterm mortality, making LT desirable in this group. Balance between the dynamics of ACLF and the allocation of the organs has not been found in the actual clinical practice. Timely evaluation and admission to the LT waiting list and prioritization of patients with ACLF within the narrow window of opportunity improves outcome and reduces futility. Careful selection of patients and timely LT saves precious life. Hence, ACLF patients should receive priority on LT wait list.